后COVID粘菌病 - 概念性病因学和新的治疗选择
Maitree Bavishi1,2, Shaji Thomas3, Preeti Parmeswaran Nair4
1Gujarat Cancer Research Centre (GCRI), Ahmedabad, India.
Journal of maxillofacial and oral surgery
|December 2, 2024
概括
后COVID粘性菌,一种真菌感染,会影响患者,原因不仅仅是糖尿病,包括凝血病. 将抗真菌药物与纤维解菌剂结合起来,有望在这些具有挑战性的病例中改善恢复.
科学领域:
- 传染性疾病 传染性疾病
- 菌类学 菌类学是指菌类学.
- 关键护理医学 关键护理医学
背景情况:
- 冠状病毒疾病2019 (COVID-19) 流行病导致机会性感染的增加.
- 粘菌菌是一种严重的真菌感染,与COVID-19患者密切相关.
- 传统的危险因素包括类固醇诱导的免疫抑制,糖尿病,缺氧和代谢酸性酸化.
研究的目的:
- 探索COVID后粘膜菌病的不寻常表现,特别是在非糖尿病年轻患者中.
- 调查凝血病和微栓塞在COVID后粘膜瘤病理生理学中的潜在作用.
- 提出后COVID粘膜菌病的新型治疗策略.
主要方法:
- 临床观察和科学文献对COVID后粘性肌肉病的综述.
- 根据观察到的患者表现和已知的疾病机制生成假设.
- 一种新的治疗方法的概念框架,该方法结合了抗真菌和纤维溶解疗法.
主要成果:
- 鉴定凝血病和微栓塞作为COVID后粘膜瘤的潜在贡献因素.
- 证明将抗真菌药物与纤维溶解剂结合使用可能减少微凝血病.
- 预计在拟议的组合疗法下,恢复率的增加和粘膜菌的改善愈合.
结论:
- 后COVID粘膜菌可能与常规粘膜菌不同,即使在非糖尿病患者中也是如此.
- 凝血病和微血管事件被假设为真菌入侵创造一个利基.
- 抗真菌药物和纤维溶解剂的联合治疗为COVID后粘膜瘤提供了一个有前途的新治疗途径.
相关概念视频
01:29Fungal Group Zygomycota
Zygomycota, previously classified as a distinct fungal group, are primarily terrestrial, saprophytic molds that play a crucial role as decomposers. Recent phylogenetic studies have revealed that these fungi are now divided into two major clades — Mucoromycota, which includes many symbiotic species, and Zoopagomycota, which primarily consists of parasitic and pathogenic fungi. These groups exhibit distinct ecological roles and reproductive strategies while sharing key structural and...
01:24Cystic Fibrosis: Management
141
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
141
01:28Pneumonia IV: Management
299
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
299
01:28Pulmonary Tuberculosis V
170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170